Fibrosis is associated with almost all forms of chronic cardiac and skeletal muscle diseases. The accumulation of extracellular matrix impairs the contractility of muscle cells contributing to organ failure. Transforming growth factor beta (TGF-β) plays a pivotal role in fibrosis, activating pro-fibrotic gene programs via phosphorylation of SMAD2/3 transcription factors. However, the mechanisms that control dephosphorylation of SMAD2/3 have remained poorly characterized. Here we show that tissue non-specific alkaline phosphatase (TNAP) is highly upregulated in hypertrophic hearts and in dystrophic skeletal muscles, and the abrogation of TGF-β signalling in TNAP positive cells reduces vascular and interstitial fibrosis. We show that TNAP co-localizes and interacts with SMAD2. TNAP inhibitor MLS-0038949 increases SMAD2/3 phosphorylation, while TNAP overexpression reduces SMAD2/3 phosphorylation and the expression of downstream fibrotic genes. Overall our data demonstrate that TNAP negatively regulates TGF-β signalling and likely represents a mechanism to limit fibrosis.
Introduction
Fibrosis accompanies many chronic diseases and is a common response to injury. It is characterized by excessive production and accumulation of collagen and other extracellular matrix (ECM) components, cellular dysfunction and loss of tissue architecture that eventually lead to organ failure (Ueha et al., 2012) . Fibrosis can affect many organs, including heart and skeletal muscle, and has become a major cause of death in the developed world.
Fibrosis is an integral component of most cardiac pathological conditions and can be associated with cardiomyocyte death (Frangogiannis, 2012) , pressure or volume overload (Berk et al., 2007) , hypertrophic cardiomyopathy (Kania et al., 2009 ) and toxic insults (Bernaba et al., 2010) .
Skeletal muscle fibrosis accompanies aging, in which case gradual muscle loss leads to the accumulation of adipose tissue and ECM (Alnaqeeb et al., 1984; Wood et al., 2014) . Fibrosis occurs early in congenital muscular dystrophies and impairs muscle function and regeneration (Serrano and Munoz-Canoves, 2017; Tedesco and Cossu, 2012) . In both cardiac and skeletal muscle, fibrosis increases the stiffness of the tissue, thereby directly impairing muscle cell contraction.
The molecular pathways involved in fibrosis are well known and common for the two organs. Transforming Growth Factor beta (TGF-β), in addition to being a major morphogen during development, is one of the main signaling molecules initiating fibrosis and is secreted by many cell types in the injured tissue. Its activity is controlled by proteolytic cleavage of a precursor, eventually bound to inhibitory proteins and subsequently released by proteases. Active TGF-β binds to the serine threonine protein kinases receptors (termed TGF-β receptor type I and type II) and induces the phosphorylation and activation of SMAD2/3 transcription factors (also known as receptor regulated SMADs or R-SMADs) (Heldin et al., 1997; Zi et al., 2012) . The phosphorylation of R-SMADs triggers their association with SMAD4, leading to their nuclear translocation, where they control the transcription of profibrotic genes. Finally, the dephosphorylation of R-SMADs promotes their exit from the nucleus and the end of the signaling (Bruce and Sapkota, 2012) . As a central regulator of a number of physiologically important processes TGFβ signaling is highly regulated. Cellular susceptibility is determined by receptor endocytosis via clathrin and caveolin dependent pathways (Di Guglielmo et al., 2003) . Depletion of TGFβ ligand defines the transcriptional response and is achieved by TGFβ binding to the cell surface or its cellular uptake (Clarke et al., 2009) . The duration and temporal dynamics of ligand availability influence downstream signaling response, as repeated pulses of TGFβ can lead to long-term sustained response (Zi et al., 2011) . Several posttranslational modifications are capable of regulating R-SMAD activity. These include ubiquitinylation (Dupont et al., 2012; Dupont et al., 2005; Episkopou et al., 2001; Lin et al., 2000; Zhu et al., 1999) , acetylation (Gronroos et al., 2002) , parpylation (Lonn et al., 2010) , sumoylation (Miles et al., 2008) and phosphorylation at different serine residues (Kretzschmar et al., 1997) . Rapid inactivation of R-SMADs can be achieved by dephosphorylation. However, to date only one R-SMAD phosphatase, has been identified for the TGF-β pathway (Lin et al., 2006) . Identification of new R-SMAD phosphatases would enable efficient attenuation of pro-fibrotic signaling in acute and chronic diseases.
Tissue Non Specific Alkaline Phosphatase (TNAP) is an enzyme widely expressed in many organs. It is involved in bone mineralization and mutations in the TNAP gene have been associated with hypophosphatasia, a rare inherited disorder, characterized by defective bone mineralization (Mornet et al., 2001) . Recently TNAP has been associated with vascular calcification (Romanelli et al., 2017; Sheen et al., 2015) and cardiac fibro-calcification (Herencia et al., 2015) . Its role in fibrosis and in the context of TGF-β signaling has not been addressed.
In the present study we demonstrate that TNAP negatively regulates TGF-β signaling pathway by regulating the level of phosphorylation of SMAD 2/3. We show that TNAP is highly induced in hypertrophic hearts and dystrophic skeletal muscle and the abrogation of TGF-β signaling in TNAP positive cells reduces vascular and interstitial fibrosis. TNAP interacts with SMAD2 and its overexpression decreases SMAD phosphorylation and the expression of downstream fibrotic genes.
Results
We previously established TNAP expression in skeletal muscle and demonstrated that its high activity marks perivascular cells (Dellavalle et al., 2007) . In contrast, we found that TNAP is more widely expressed in healthy mouse heart. We detected alkaline phosphatase activity mainly in the interstitium (Figure 1a ,b) but also in cardiomyocytes ( Figure 1c ). At higher resolution ( Figure 1d ) AP activity co-localized both with endothelial (VE-Cadherin +) and perivascular (NG2+) cells and also extended outside of the small vessels ( fig. 1d ). Of the three AP isoforms, Intestinal, Embryonic and Non Specific, only the latter is expressed in the heart at any developmental stage examined ( Fig. 1e ). When TNAP-Cre ERT mice (Dellavalle et al. 2011 ) were crossed to NGZ reporter mice, LacZ activity was detected in many areas of the heart (Figure 1f) . Additional examples of TNAP localization in adult healthy heart are shown in Supplementary Figure 1 .
Angiotensin II infusion increases TNAP expression in cardiomyocytes and cardiac fibroblast in vivo.
We next analysed changes in TNAP activity in response to fibrosis. We used a model of Angiotensin II-induced cardiac hypertrophy, which is known to cause fibrosis after few days (Crowley et al., 2006) . We implanted subcutaneous mini-pumps releasing Angiotensin II (Ang II) (2.8mg/kg per day) for two weeks in 10 weeks old C57/BL6J mice. We analysed the hearts of treated mice for the presence of hypertrophy and fibrosis. As expected, the treatment with Ang II caused cardiomyocytes hypertrophy and led to an increase in Tenascin C positive areas compared with mice treated with saline solution (Sham) ( Supplementary Fig. 2a -i). Moreover, the expression of the fibrotic genes Fibronectin1, Tenascin C, Sma2, Vimentin and Collagen1a2 was significantly upregulated in Ang II treated mice compared with the control ( Supplementary Fig. 2j -p).
We took advantage of this disease model to analyse the expression of Tnap.
Interestingly, we found a significant increase in the number of TNAP + cells in hypertrophic hearts in comparison to the control ( Fig. 2a -c; n=5 for each group).
Moreover, we detected an upregulation of Tnap expression by RT-qPCR ( Figure 2d ).
In order to understand which cell types express TNAP in physiological and pathological conditions, we stained the heart sections for TNAP and Laminin, Vimentin and PECAM, which allow identification of cardiomyocytes basal lamina, cardiac interstitial and endothelial cells respectively, and using confocal microscopy counted the number of double positive cells in a 77 mm 2 area. We confirmed that all three cells types analysed expressed TNAP in normal heart (TNAP/PECAM + cells 16.6 ± 6%, TNAP/Laminin + cells 26 ± 5.4%, TNAP/Vimentin + /PECAMcells 27 ± 5.6%, n=3 mice, mean ± s.d.). Remarkably, in the Ang II treated mice the number of cells expressing TNAP significantly increased in all three different cell populations (TNAP + /PECAM + cells 30.5 ± 4.1%; TNAP + /Laminin + cells 42.4 ± 1.5%, TNAP + /Vimentin + /PECAMcell;s 49.3 ± 6%, n=3 mice, mean ± s.d., P<0.001, twotailed t-test) ( Fig. 2e-m) . These data prove that in hypertrophic hearts TNAP is significantly up regulated in cardiac myocytes, endothelial cells and interstitial cells.
However, it is important to notice that, under normal condition only a minority of cells in the heart express TNAP and even if this number almost doubles in Ang treated animal, it remains confined to less than half of total cardiac cells.
The abrogation of TGF-β signaling in TNAP positive cells reduces fibrosis in the heart and skeletal muscle
Since the increased number of TNAP + cells is preferentially localised in Tenascin C positive regions ( Fig. 2a ,b, k, l), we reasoned that TNAP + cells might have a role in the regulation of fibrosis upon Ang II treatment. TNAP is widely expressed in many different cells so that a cardiac specific knock out would be technically very challenging in this context as Cre should be driven by al least three (cardiac, endothelial and interstitial) different promoters. Therefore, to prove that TNAP expressing cells are in fact involved in cardiac fibrosis, despite being a minority of total cardiac cells, we inactivated TGF-β signalling specifically in TNAP positive cells. To achieve this goal we took advantage of an inducible conditional knockout Tnap cre ;Tgfβr2 floxed mouse (Chytil et al., 2002; Dellavalle et al., 2011) . This strain is characterized by the inactivation, upon tamoxifen injection, of TGF-β Receptor 2 (TGF-βR2) in TNAP expressing cells. We first verified by immunofluorescence whether TNAP + cells express TGF-βR2 and found that virtually all TNAP + cells are also positive for TGF-βR2, both in Sham and Ang II treated mice ( Fig. 3a, b ). We then injected the Tnap cre ;Tgfβr2 fl/fl transgenic mice with 100mg/kg of tamoxifen (TAM) once a day for 5 days; at day 7 we implanted subcutaneous mini-pumps releasing 2.8mg/kg per day of Ang II for 2 weeks (Fig. 3c ). We verified Cre recombination efficiency on the total heart of the Tnap cre ;Tgfβr2 fl/fl mice by RT-qPCR for the exon 4 of the Tgf-βr2, the exon excised by Cre recombinase (Chytil et al., 2002) , and found approximately 50% reduction in its expression in Tnap cre ;Tgfβr2 fl/fl compared to control ( Fig. 3d ). We measuring the area of cardiomyocytes, but we found no difference in cell size and in overall hypertrophy within the two groups ( Fig. 3m-q) , indicating that the reduction of fibrosis is not accompanied by a reduction in hypertrophy. We next characterized the expression of fibrotic genes by RT-qPCR in the three sample groups and found a significant reduction in Collagen 1a2 and Vimentin expression in the Tnap cre ;Tgf-βr2 fl/fl mice treated with Ang II compared with the controls (Fig. 3r ,s), while Sma2 expression did not change ( Fig. 3t ). Moreover, also immunostaining with antibodies against collagen 1 and MMP1 showed a dramatic reduction of areas of fibrosis, as also confirmed by Azan-Mallory staining (Supplementary figure 4) . These data prove that TNAP is specifically expressed and upregulated in cells with active TGF-β signalling that underlie cardiac fibrosis. It is remarkable that a 50% reduction of expression in a minority of the cardiac cell population leads to a dramatic decrease in the level of fibrosis, suggesting a specific role of TNAP+ cells in regulating fibrosis.
Since it has been previously shown that TNAP is up regulated in dystrophic muscles (Diaz-Manera et al., 2012) we asked whether the abrogation of TGF-β signalling in TNAP + cells in dystrophic mice could reduce skeletal muscle fibrosis. We took advantage of the alpha-sarcoglycan deficient (Sgca-null) mice, a model for Limb-Girdle Muscular Dystrophy 2D (Duclos et al., 1998 ) that develop severe fibrosis after 2 months of age. We generated a triple transgenic strain by crossing the Sgca null mice with the Tnap cre ;Tgf-βr2 fl/fl mouse. We injected 6-7 days old pups with tamoxifen for three days and sacrificed at 2 months old ( Fig.4a ). We measured the recombination efficiency of Cre recombinase by RT-qPCR and western blot ( Fig.4, b ,c) and found it to be 50%. We next analysed the extent of fibrosis by measuring the percentage of Tenascin C positive regions and found a significant decrease in fibrosis in the Tibialis Anterior (TA), the Gastrocnemius (GA) and the Diaphragm (DIA) of the Sgca null Tnap cre ;Tgf-βr2 fl/fl mice compared with the Sgca null controls ( Fig.4 d-g) . We
analysed the level of Collagen1a2 by immunofluorescence ( Fig.4h ) and the expression level of Collagen1a2, Sma2 and Vimentin by RT-qPCR ( Fig.4 i-k). We observed a significant reduction of their expression in the Sgca null Tnap cre ;Tgf-βr2 fl/fl mice compared with the Sgca null controls. In order to reveal whether the reduction of fibrosis in the triple transgenic mice is sufficient to improve muscle strength and function, we measured muscle grip strength by placing mice on an upside down grid (Bonetto et al., 2015) . Wild-type mice started to explore the environment and spent little time in the same location. In contrast Sgca knockout mice spent 26% of the total time without moving, which importantly decreased to only 10% in the triple transgenic mice ( Fig.4l ) (n=4 each group). These data suggest that the reduction in fibrosis is associated with improved skeletal muscle function. Overall the data so far demonstrate that cells that express TNAP in fibrotic cardiac and skeletal muscle are of pivotal significance in the TGF-β-dependent development of the pathology as inhibition of TGF-β signalling in these cells is sufficient to limit fibrosis.
TNAP inhibits SMAD2/3 phosphorylation and limits the expression of downstream fibrotic genes
Since we obtained similar results in cardiac and skeletal muscle models of fibrosis, we hypothesized that TNAP may have a role in the regulation of TGF-β signalling and that this role is conserved in both tissues. Being a phosphatase, TNAP could be involved in the dephosphorylation of p-SMAD2/3 and have thereby a regulatory role in the transcription of fibrotic genes. In order to test our hypothesis we first verified if TNAP and p-SMAD2/3 co-localize within the cell. We stained sections for TNAP and p-SMAD2/3 and saw that both of them partially co-localise in the peri-nuclear region ( Fig. 5a ). We confirmed their co-localization also in vitro. We transfected C2C12 skeletal myogenic cells with EYFP-SMAD2 and mCherry-TNAP plasmids and confirmed that the two proteins co-localize in intracellular vesicular compartments around the nucleus (Fig. 5b) . Interestingly TNAP and SMAD2 co-localization was present in both Sham and Ang II treated mice ( Fig. 5a ). We found that TNAP not only co-localizes with SMAD2 but also physically interacts with it. We proved this by using Proximity Ligation Assay (PLA) (Shah et al., 2017) ( Fig. 5c ) and coimmunoprecipitation on C2C12 transfected with Myc-TNAP ( Supplementary Fig. 5 ).
Our results show that endogenous SMAD2 interacts with Myc-TNAP. Notably, the TNAP-SMAD2 interaction not only occurs upon TGF-β stimulation, but also, at lower level, under control conditions. In order to understand if this interaction has a functional relevance on TGF-β signalling we treated cardiac fibroblast with TGF-β1 (5ng/ml) and the specific TNAP inhibitor MLS-0038949 (Crowley et al., 2006) (200nM) for 1 hour and analysed SMAD2/3 phosphorylation by western blot. The cells treated with TGF-β1 and TNAP inhibitor showed a significant increase in SMAD2/3 phosphorylation compared with cells treated with only TGF-β1 ( Fig.5d) (n=3 independent experiments), suggesting that the blockade of TNAP leads to enhanced TGF-β signalling. To provide further evidence for TNAP regulation of SMAD2/3 activity we overexpressed plasmid encoding for Myc-TNAP in C2C12 skeletal muscle cells and stimulated the cells with TGF-β1 (5ng/ml). We chose this cell line because it has no detectable TNAP expression ( Fig. 5e ). We verified that the plasmid was functional by staining C2C12 with a functional assay for AP ( Fig. 5e,f) .
Upon TGF-β1 stimulation we detected a decrease in SMAD2/3 phosphorylation in Myc-TNAP overexpressing cells compared with the GFP control ( Fig. 5g ). Inhibition of SMAD2/3 phosphorylation was not dramatic because on average approximately 20-30% of C2C12 cells are transiently transfected. Together these data prove that TNAP is capable and in itself sufficient to limit SMAD2/3 phosphorylation. We next analysed the expression of fibrotic genes downstream p-SMAD2/3 by RT-qPCR and observed that Fibronectin1, Collagen1a2 and Tenascin C expression were downregulated in Myc-TNAP overexpressing cells compared with the control (Fig.   5h ), indicating that TNAP induced dephosphorylation of p-SMAD2/3 is sufficient to limit fibrotic genes transcription. Taken together these data indicate that TNAP regulates SMAD2/3 phosphorylation levels and is a direct attenuator of cellular profibrotic signaling pathways.
Discussion
Despite ever increasing understanding of the molecular processes that trigger fibrosis across different organs there are only few therapies available and most of them only indirectly target fibrotic processes (Rockey et al., 2015) . TGF-β1 binding to the receptors on the plasma membrane leads to the phosphorylation of R-SMADs, their translocation into the nucleus and transcription of pro-fibrotic genes. Given the importance of TGF-β signaling and the phosphorylation of R-SMADs in fibrosis, the identification of phosphatases, able to switch off the TGF-β pathway, has been of interest in the past ten years since they could also be targets for anti-fibrotic drugs.
Nevertheless, until now, only one phosphatase,
has been identified (Lin et al., 2006) . Here we show that TNAP is able to dephosphorylate SMAD2/3 and consequently limit the transcription of pro-fibrotic genes.
An abundant literature exists on TNAP function in bone development and calcification (Byon et al., 2008; Millan, 2013 ); yet the role of TNAP in the heart has only been partly elucidated. TNAP overexpression has recently been associated with increased cardiac fibrosis and vascular calcification. Sheen et al. demonstrated that the induced expression of TNAP in vascular smooth muscle cells is sufficient to cause medial vascular calcification (Sheen et al., 2015) . Similarly Romanelli and colleagues showed that TNAP overexpression in vascular endothelium in mice leads to arterial calcification and subsequent coronary atherosclerosis (Romanelli et al., 2017) . These studies described the effects of sustained TNAP overexpression, but the role of TNAP under physiological levels of expression has not been addressed. Indeed, it is counterintuitive that tissues where calcification is exclusively pathological, have maintained TNAP expression during evolution. This suggests that TNAP may also play beneficial roles in striated muscle that is eventually overridden by sustained fibrotic stimuli; however this role has thus far remained unknown. Here we analysed two different models of fibrosis: rapid-onset cardiac fibrosis induced by the hypertensive molecule Ang II, and chronic skeletal muscle fibrosis in the Sgca null mice. We confirm earlier evidence showing that TNAP is upregulated in tissue fibrosis (Herencia et al., 2015 ) (Gan et al., 2014) , but also show here that the number of cells expressing TNAP increases in both heart and skeletal muscle. Furthermore, as the abrogation of TGF-β signaling in TNAP positive cells dramatically reduces vascular and interstitial fibrosis, we can conclude that TNAP is actively expressed in cells driving tissue fibrosis. Since in the heart, not only interstitial/perivascular cells but also endothelial cells and cardiomyocytes participate to the process (though likely to a minor extent), it is interesting to note that TNAP has a similar pattern of expression, being more abundant in interstitial/perivascular cells but also present in the other cell types of the heart.
TGF-β signaling relies on trafficking of activated phosphorylated R-SMAD proteins from the plasma membrane to the nucleus (Chen, 2009; Hough et al., 2012; Nakao A, 1997) . SMAD2/3 inactivation during this process would enable a cell to rapidly limit the expression of pro-fibrotic genes even in the presence of TGF-β secreted in the inflammatory tissue environment. Here we show that TNAP inhibition enhances SMAD2/3 phosphorylation whereas TNAP overexpression has the opposite effect. We demonstrate that TNAP interacts with SMAD2. Our data collectively prove that TNAP is an efficient inhibitor of SMAD2/3 and limits SMAD-dependent transcription of profibrotic genes. Intriguingly, TNAP interacts with SMAD2 even in cells that are not exposed to TGF-β1. These results demonstrate that TNAP likely has a housekeeping function during normal tissue growth and homeostasis, which explains its basal level expression in cardiac and skeletal muscle. In addition to the molecular mechanism described here, TNAP may also indirectly affect the activity of numerous phosphorylation-dependent pathways as this enzyme is known to regulate the level of cytoplasmic inorganic phosphate (Pi) ( Hessle et al., 2002) .
We show here that the ubiquitously expressed TNAP is an essential regulator of SMAD2/3-dependent TGF-β signaling in physiological conditions and in tissue fibrosis. These results provide a novel insight into the mechanisms that control the expression of extracellular matrix genes and may lead to the development of novel therapies for fibrosis.
Material and methods

Animals
Mice were maintained in pathogen-free conditions at Manchester University animal facility and fed standard rodent diet. Animal studies were performed according to the (Duclos et al., 1998) , Tnap cre mice (Dellavalle et al., 2011) and Tgfbr2 flox/flox (Chytil et al., 2002) mice were backcrossed onto C57BL/6 mice (Charles River Laboratories Inc, Wilmington, MA, USA) and were genotyped as previously described (Dellavalle et al., 2011) . Mice were culled by administration of isoflurane and consequent cervical dislocation at appropriate time points. Hearts and muscles were collected in ice-cold PBS and then embedded in glue or OCT inclusion media. Samples were stored at -80°C before processing. T5648) was dissolved in corn oil (Sigma Aldrich, Cat. No. C8267) and injected at the following concentrations and time points: 0.3 mg/mouse in 6 days old pups once a day for 3 consecutively days and 3 mg/mouse in 10 weeks old mice once a day for 5
Osmotic Minipump Infusion of Angiotensin II and Tamoxifen administration
consecutively days.
Grip test
The four limb-hanging test (also known as Kondziella's inverted screen test) (Bonetto et al., 2015) represents a method to assess muscle strength using all four limbs and to determine the general condition over time. In this study, we modified this method to improve its variability and consistency. Briefly we placed the mice upside down on a grid (50cm x 30cm) and we counted the number of seconds in which the mice were not moving on the grid, over a total period of 50 sec each mice. We calculated the resting time on the grid as the average of 3 different tests for each mouse, and we analysed 4 mice per each group.
PLA and Immunofluorescence
PLA was performed according to the manufacturer's instructions using the Duolink In Situ Orange Kit Goat/Rabbit (Sigma Aldrich, Cat. No. DUO92106).
Immunofluorescence was performed as previously described (Arno et al., 2014) .
Briefly sections (5 µm Specific primers were used for gene expression analysis:
Statistics.
Data are expressed as the mean ± standard deviation (SD) or standard error of the mean (S.E.M.) of independent experiments. Comparisons were made using the unpaired t-test. Statistical tests were carried out using PRISM6.0e (GraphPad Software, La Jolla, CA). A p-value less than 0.05 was considered statistically significant.
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